By Chris Wack

 

Spero Therapeutics Inc. said it submitted a new drug application to the U.S. Food and Drug Administration seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections, including pyelonephritis, caused by susceptible microorganisms.

The biopharmaceutical company said that if approved, tebipenem HBr would be the only oral carbapenem antibiotic available for use in cUTI.

Spero said it will work with the FDA during the NDA review process as it prepares for tebipenem HBr's anticipated launch in the second half of 2022.

The NDA submission includes previously communicated positive data from its Phase 3 trial. The data showed that the trial met its primary endpoint by demonstrating that oral tebipenem HBr was statistically non-inferior to IV ertapenem in the treatment of patients with cUTI and patients with acute pyelonephritis.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

October 28, 2021 08:31 ET (12:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Spero Therapeutics Charts.
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Spero Therapeutics Charts.